International Journal of Infection

Published by: Kowsar

Antibiotic Resistance Mechanisms Focusing on Quinolones Resistance in Vibrio CHOLERAE

Lawaly Maman Manzo 1 , * , Bassira B. Issaka 1 , Issaka Seidou 1 and Jibir Zanguina 1
Authors Information
1 Bacteriology and Virology Unit, Centre for Medical and Health Research (CERMES), Niamey, Niger
Article information
  • International Journal of Infection: July 2017, 4 (3); e40622
  • Published Online: August 31, 2016
  • Article Type: Review Article
  • Received: July 25, 2016
  • Revised: August 10, 2016
  • Accepted: August 15, 2016
  • DOI: 10.5812/iji.40622

To Cite: Maman Manzo L, B. Issaka B, Seidou I, Zanguina J. Antibiotic Resistance Mechanisms Focusing on Quinolones Resistance in Vibrio CHOLERAE, Int J Infect. 2017 ; 4(3):e40622. doi: 10.5812/iji.40622.

Abstract
Copyright © 2016, Infectious Diseases and Tropical Medicine Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Acknowledgements
Footnote
References
  • 1. Leibovici-Weissman Y, Neuberger A, Bitterman R, Sinclair D, Salam MA, Paul M. Antimicrobial drugs for treating cholera. Cochrane Database Syst Rev. 2014; (6)[DOI][PubMed]
  • 2. Seas C, Gotuzzo E. Vibrio cholerae (Cholera). 2014;
  • 3. Bhattacharya SK, Bhattacharya MK, Dutta P, Dutta D, De SP, Sikdar SN, et al. Double-blind, randomized, controlled clinical trial of norfloxacin for cholera. Antimicrob Agents Chemother. 1990; 34(5): 939-40[PubMed]
  • 4. Gotuzzo E, Cieza J, Estremadoyro L, Seas C. Cholera. Lessons from the epidemic in Peru. Infect Dis Clin North Am. 1994; 8(1): 183-205[PubMed]
  • 5. Moolasart P, Eampokalap B, Supaswadikul S. Comparison of the efficacy of tetracycline and norfloxacin in the treatment of acute severe watery diarrhea. Southeast Asian J Trop Med Public Health. 1998; 29(1): 108-11[PubMed]
  • 6. Seijo AC, Fernandez M, Campos C, Cernigoi BE, Nogueras M, San Juan J, et al. Norfloxacin monodose use in patients with cholera in Salta Argentina. Rev Inst Med Trop Sao Paulo. 1996; 38(3): 217-9[PubMed]
  • 7. Doganci L, Gun H, Baysallar M, Albay A, Cinar E, Haznedaroglu T. Short-term quinolones for successful eradication of multiply resistant Vibrio cholerae in adult patients. Scand J Infect Dis. 1995; 27(4): 425-6[PubMed]
  • 8. Gotuzzo E, Seas C, Echevarria J, Carrillo C, Mostorino R, Ruiz R. Ciprofloxacin for the treatment of cholera: a randomized, double-blind, controlled clinical trial of a single daily dose in Peruvian adults. Clin Infect Dis. 1995; 20(6): 1485-90[PubMed]
  • 9. Khan W, Bennish ML, Seas C, Khan EH, Ronan A, Dhar U, et al. Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae O1 or O139. The Lancet. 1996; 348(9023): 296-300[DOI]
  • 10. Jesudason MV, John TJ. Transferable trimethoprim resistance of Vibrio cholerae O1 encountered in southern India. Trans R Soc Trop Med Hyg. 1990; 84(1): 136-7[PubMed]
  • 11. Faruque AS, Alam K, Malek MA, Khan MG, Ahmed S, Saha D, et al. Emergence of multidrug-resistant strain of Vibrio cholerae O1 in Bangladesh and reversal of their susceptibility to tetracycline after two years. J Health Popul Nutr. 2007; 25(2): 241-3[PubMed]
  • 12. Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966; 45(4): 493-6[PubMed]
  • 13. Chander J, Kaistha N, Gupta V, Mehta M, Singla N, Deep A, et al. Epidemiology & antibiograms of Vibrio cholerae isolates from a tertiary care hospital in Chandigarh, north India. Indian J Med Res. 2009; 129(5): 613-7[PubMed]
  • 14. Saha D, Karim MM, Khan WA, Ahmed S, Salam MA, Bennish ML. Single-dose azithromycin for the treatment of cholera in adults. N Engl J Med. 2006; 354(23): 2452-62[DOI][PubMed]
  • 15. Krishna BV, Patil AB, Chandrasekhar MR. Fluoroquinolone-resistant Vibrio cholerae isolated during a cholera outbreak in India. Trans R Soc Trop Med Hyg. 2006; 100(3): 224-6[DOI][PubMed]
  • 16. Garg P, Sinha S, Chakraborty R, Bhattacharya SK, Nair GB, Ramamurthy T, et al. Emergence of fluoroquinolone-resistant strains of Vibrio cholerae O1 biotype El Tor among hospitalized patients with cholera in Calcutta, India. Antimicrob Agents Chemother. 2001; 45(5): 1605-6[PubMed]
  • 17. Mercy N, Mohamed AA, Zipporah N, Chowdhury G, Pazhani GP, Ramamurthy T, et al. Phenotypic and genetic characterization of Vibrio cholerae O1 isolated from various regions of Kenya between 2007 and 2010. Pan Afr Med J. 2014; 19: 8[DOI][PubMed]
  • 18. Mandal J, Dinoop KP, Parija SC. Increasing antimicrobial resistance of Vibrio cholerae OI biotype E1 tor strains isolated in a tertiary-care centre in India. J Health Popul Nutr. 2012; 30(1): 12-6[PubMed]
  • 19. Eibach D, Herrera-Leon S, Gil H, Hogan B, Ehlkes L, Adjabeng M, et al. Molecular Epidemiology and Antibiotic Susceptibility of Vibrio cholerae Associated with a Large Cholera Outbreak in Ghana in 2014. PLoS Negl Trop Dis. 2016; 10(5): 4751[DOI][PubMed]
  • 20. Espeli O, Marians KJ. Untangling intracellular DNA topology. Mol Microbiol. 2004; 52(4): 925-31[DOI][PubMed]
  • 21. Drlica K, Malik M, Kerns RJ, Zhao X. Quinolone-mediated bacterial death. Antimicrob Agents Chemother. 2008; 52(2): 385-92[DOI][PubMed]
  • 22. Sugino A, Peebles CL, Kreuzer KN, Cozzarelli NR. Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc Natl Acad Sci U S A. 1977; 74(11): 4767-71[PubMed]
  • 23. Willmore E, de Caux S, Sunter NJ, Tilby MJ, Jackson GH, Austin CA, et al. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood. 2004; 103(12): 4659-65[DOI][PubMed]
  • 24. Chen CR, Malik M, Snyder M, Drlica K. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage. J Mol Biol. 1996; 258(4): 627-37[DOI][PubMed]
  • 25. Everett MJ, Jin YF, Ricci V, Piddock LJ. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob Agents Chemother. 1996; 40(10): 2380-6[PubMed]
  • 26. Vila J, Ruiz J, Marco F, Barcelo A, Goni P, Giralt E, et al. Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrob Agents Chemother. 1994; 38(10): 2477-9[PubMed]
  • 27. Quilici ML, Massenet D, Gake B, Bwalki B, Olson DM. Vibrio cholerae O1 variant with reduced susceptibility to ciprofloxacin, Western Africa. Emerg Infect Dis. 2010; 16(11): 1804-5[DOI][PubMed]
  • 28. Lubelski J, Konings WN, Driessen AJ. Distribution and physiology of ABC-type transporters contributing to multidrug resistance in bacteria. Microbiol Mol Biol Rev. 2007; 71(3): 463-76[DOI][PubMed]
  • 29. Pao SS, Paulsen IT, Saier MH. Major facilitator superfamily. Microbiol Mol Biol Rev. 1998; 62(1): 1-34[PubMed]
  • 30. Kuroda T, Tsuchiya T. Multidrug efflux transporters in the MATE family. Biochim Biophys Acta. 2009; 1794(5): 763-8[DOI][PubMed]
  • 31. Jack DL, Yang NM, Saier MH. The drug/metabolite transporter superfamily. Eur J Biochem. 2001; 268(13): 3620-39[PubMed]
  • 32. Nikaido H, Takatsuka Y. Mechanisms of RND multidrug efflux pumps. Biochim Biophys Acta. 2009; 1794(5): 769-81[DOI][PubMed]
  • 33. Paulsen IT, Brown MH, Skurray RA. Proton-dependent multidrug efflux systems. Microbiol Rev. 1996; 60(4): 575-608[PubMed]
  • 34. Putman M, van Veen HW, Konings WN. Molecular properties of bacterial multidrug transporters. Microbiol Mol Biol Rev. 2000; 64(4): 672-93[PubMed]
  • 35. Begum A, Rahman MM, Ogawa W, Mizushima T, Kuroda T, Tsuchiya T. Gene cloning and characterization of four MATE family multidrug efflux pumps from Vibrio cholerae non-O1. Microbiol Immunol. 2005; 49(11): 949-57[PubMed]
  • 36. Heidelberg JF, Eisen JA, Nelson WC, Clayton RA, Gwinn ML, Dodson RJ, et al. DNA sequence of both chromosomes of the cholera pathogen Vibrio cholerae. Nature. 2000; 406(6795): 477-83[DOI][PubMed]
  • 37. Morita Y, Kodama K, Shiota S, Mine T, Kataoka A, Mizushima T, et al. NorM, a putative multidrug efflux protein, of Vibrio parahaemolyticus and its homolog in Escherichia coli. Antimicrob Agents Chemother. 1998; 42(7): 1778-82[PubMed]
  • 38. Colmer JA, Fralick JA, Hamood AN. Isolation and characterization of a putative multidrug resistance pump from Vibrio cholerae. Mol Microbiol. 1998; 27(1): 63-72[PubMed]
  • 39. Baranwal S, Dey K, Ramamurthy T, Nair GB, Kundu M. Role of active efflux in association with target gene mutations in fluoroquinolone resistance in clinical isolates of Vibrio cholerae. Antimicrob Agents Chemother. 2002; 46(8): 2676-8[PubMed]
  • 40. Bina JE, Provenzano D, Wang C, Bina XR, Mekalanos JJ. Characterization of the Vibrio cholerae vexAB and vexCD efflux systems. Arch Microbiol. 2006; 186(3): 171-81[DOI][PubMed]
  • 41. Bina XR, Provenzano D, Nguyen N, Bina JE. Vibrio cholerae RND family efflux systems are required for antimicrobial resistance, optimal virulence factor production, and colonization of the infant mouse small intestine. Infect Immun. 2008; 76(8): 3595-605[DOI][PubMed]
  • 42. Van Bambeke F, Michot JM, Tulkens PM. Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics. J Antimicrob Chemother. 2003; 51(5): 1067-77[DOI][PubMed]
  • 43. Okuda J, Hayashi N, Wakahara Y, Gotoh N. Reduced expression of the vca0421 gene of Vibrio cholerae O1 results in innate resistance to ciprofloxacin. Antimicrob Agents Chemother. 2010; 54(11): 4917-9[DOI][PubMed]
  • 44. Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs. 2004; 64(2): 159-204[PubMed]
  • 45. Chen J, Morita Y, Huda MN, Kuroda T, Mizushima T, Tsuchiya T. VmrA, a member of a novel class of Na(+)-coupled multidrug efflux pumps from Vibrio parahaemolyticus. J Bacteriol. 2002; 184(2): 572-6[PubMed]
  • 46. Huda N, Lee EW, Chen J, Morita Y, Kuroda T, Mizushima T, et al. Molecular cloning and characterization of an ABC multidrug efflux pump, VcaM, in Non-O1 Vibrio cholerae. Antimicrob Agents Chemother. 2003; 47(8): 2413-7[PubMed]
  • 47. Woolley RC, Vediyappan G, Anderson M, Lackey M, Ramasubramanian B, Jiangping B, et al. Characterization of the Vibrio cholerae vceCAB multiple-drug resistance efflux operon in Escherichia coli. J Bacteriol. 2005; 187(15): 5500-3[DOI][PubMed]
  • 48. Bag PK, Maiti S, Sharma C, Ghosh A, Basu A, Mitra R, et al. Rapid spread of the new clone of Vibrio cholerae O1 biotype El Tor in cholera endemic areas in India. Epidemiol Infect. 1998; 121(2): 245-51[PubMed]
  • 49. Clark CA, Purins L, Kaewrakon P, Manning PA. VCR repetitive sequence elements in the Vibrio cholerae chromosome constitute a mega-integron. Mol Microbiol. 1997; 26(5): 1137-8[PubMed]
  • 50. Glass RI, Huq MI, Lee JV, Threlfall EJ, Khan MR, Alim AR, et al. Plasmid-borne multiple drug resistance in Vibrio cholerae serogroup O1, biotype El Tor: evidence for a point-source outbreak in Bangladesh. J Infect Dis. 1983; 147(2): 204-9[PubMed]
  • 51. Finch MJ, Morris JG, Kaviti J, Kagwanja W, Levine MM. Epidemiology of antimicrobial resistant cholera in Kenya and East Africa. Am J Trop Med Hyg. 1988; 39(5): 484-90[PubMed]
  • 52. Korichi MN, Belhocine S, Rahal K. [Inc J plasmids identified for the first time in Vibrio cholerae El Tor]. Med Trop (Mars). 1997; 57(3): 249-52[PubMed]
  • 53. Martinez-Freijo P, Fluit AC, Schmitz FJ, Grek VS, Verhoef J, Jones ME. Class I integrons in Gram-negative isolates from different European hospitals and association with decreased susceptibility to multiple antibiotic compounds. J Antimicrob Chemother. 1998; 42(6): 689-96[PubMed]
  • 54. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis. 2006; 6(10): 629-40[DOI][PubMed]
  • 55. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, et al. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med. 2006; 12(1): 83-8[DOI][PubMed]
  • 56. Tran JH, Jacoby GA, Hooper DC. Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase. Antimicrob Agents Chemother. 2005; 49(1): 118-25[DOI][PubMed]
  • 57. Fonseca EL, Dos Santos Freitas F, Vieira VV, Vicente AC. New qnr gene cassettes associated with superintegron repeats in Vibrio cholerae O1. Emerg Infect Dis. 2008; 14(7): 1129-31[DOI][PubMed]
  • 58. Burrus V, Marrero J, Waldor MK. The current ICE age: biology and evolution of SXT-related integrating conjugative elements. Plasmid. 2006; 55(3): 173-83[DOI][PubMed]
  • 59. Kim HB, Wang M, Ahmed S, Park CH, LaRocque RC, Faruque ASG, et al. Transferable quinolone resistance in vibrio cholerae. Antimicrob Agents Chemother. 2009; 54(2): 799-803[DOI]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments